VSIG4 Antibody - #DF14591

(1)   (4)  
Product: VSIG4 Antibody
Catalog: DF14591
Description: Rabbit polyclonal antibody to VSIG4
Application: WB IHC IF/ICC
Reactivity: Human, Rat
Mol.Wt.: 40/50kD; 44kD(Calculated).
Uniprot: Q9Y279

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Rat
Clonality:
Polyclonal
Specificity:
VSIG4 Antibody detects endogenous levels of VSIG4.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Complement receptor of the immunoglobulin superfamily; CRIg; Ig superfamily protein; Protein Z39Ig; UNQ317/PRO362; V set and immunoglobulin domain containing 4; V-set and immunoglobulin domain-containing protein 4; VSIG4; VSIG4_HUMAN; Z39IG;

Immunogens

Immunogen:

A synthesized peptide derived from human VSIG4.

Uniprot:

Q9Y279(VSIG4_HUMAN) >>Visit HPA database.

Gene(ID):
VSIG4(11326)
Expression:
Q9Y279 VSIG4_HUMAN:

Abundantly expressed in several fetal tissues. In adult tissues, highest expression in lung and placenta. Expressed in resting macrophages.

Sequence:
MGILLGLLLLGHLTVDTYGRPILEVPESVTGPWKGDVNLPCTYDPLQGYTQVLVKWLVQRGSDPVTIFLRDSSGDHIQQAKYQGRLHVSHKVPGDVSLQLSTLEMDDRSHYTCEVTWQTPDGNQVVRDKITELRVQKLSVSKPTVTTGSGYGFTVPQGMRISLQCQARGSPPISYIWYKQQTNNQEPIKVATLSTLLFKPAVIADSGSYFCTAKGQVGSEQHSDIVKFVVKDSSKLLKTKTEAPTTMTYPLKATSTVKQSWDWTTDMDGYLGETSAGPGKSLPVFAIILIISLCCMVVFTMAYIMLCRKTSQQEHVYEAARAHAREANDSGETMRVAIFASGCSSDEPTSQNLGNNYSDEPCIGQEYQIIAQINGNYARLLDTVPLDYEFLATEGKSVC

Research Backgrounds

Function:

Phagocytic receptor, strong negative regulator of T-cell proliferation and IL2 production. Potent inhibitor of the alternative complement pathway convertases.

Subcellular Location:

Membrane>Single-pass type I membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Abundantly expressed in several fetal tissues. In adult tissues, highest expression in lung and placenta. Expressed in resting macrophages.

Research Fields

· Organismal Systems > Immune system > Complement and coagulation cascades.   (View pathway)

References

1). Exploring the immune microenvironment of osteosarcoma through T cell exhaustion-associated gene expression: a study on prognosis prediction. Frontiers in immunology, 2023 (PubMed: 38169731) [IF=7.3]

Application: IHC    Species: Human    Sample:

Figure 12 Validation of the prognostic model using the H-score obtained by immunohistochemistry (IHC). (A) Osteosarcoma patients were categorized into low and high-risk groups based on the immunohistochemistry (IHC) results of PLEKHO2, VSIG4, MPP1, and GBP2. (B) The high-risk group exhibited a poorer survival outcome compared to the low-risk group. (C) Time-dependent ROC curves were generated in the IHC validation cohort, with AUC values of 0.800 at 1 year, 0.722 at 3 years, and 0.654 at 5 years. (D, E) The distribution of risk scores, the survival status of each patient, and a heatmap depicting the prognostic 4-gene signature were analyzed in the IHC validation cohort.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.